Open AccessLocalized peripheral neuropathic pain: topical treatment with lidocaine 700 mg medicated plaster in routine clinical practice
Author(s) -
Michael A. Überall,
Irmgard Bösl,
Els Hollanders,
Ingo Sabatschus,
Mariëlle Eerdekens
Publication year - 2022
Publication title -
pain management
Language(s) - English
Resource type - Journals
eISSN - 1758-1877
pISSN - 1758-1869
DOI - 10.2217/pmt-2021-0117
Subject(s) - medicine , tolerability , neuropathic pain , lidocaine , anesthesia , quality of life (healthcare) , pregabalin , peripheral neuropathy , adverse effect , diabetes mellitus , nursing , endocrinology
Aim: To provide real-world evidence for the effectiveness and tolerability of lidocaine 700 mg medicated plaster (LMP) in localized peripheral neuropathic pain (l-PNP) treatment compared with first-line oral medications (OM). Patients & methods: This was a noninterventional, retrospective 6-month cohort study in patients refractory to at least one recommended OM, using anonymized medical care data from the German Pain eRegistry. Treatment groups were matched by propensity scoring, considering seven predefined confounding factors. The primary effectiveness end point was the absolute change in average pain intensity index from baseline at weeks 4, 12 and 24 of treatment and over the treatment period. Results: A total of 3081 datasets were retained per treatment group. LMP provided superior pain reductions and significantly greater improvements in pain-related impairments of daily living and quality of life with significantly better tolerability (p < 0.001 for all parameters) than OM. Conclusion: These real-world data confirm the effectiveness and good tolerability of LMP for l-PNP treatment under routine medical care.